After more than a year of not-so-secret negotiations, Geron has finally auctioned off its long-stalled embryonic stem cell pipeline, handing it over to BioTime, a newly created subsidiary, in exchange for shares.
BioTime has recruited ex-Geron CEO Thomas Okarma to help revive the four long-shelved cell lines under a subsidiary of its own, Asterias. Headlining the deal is the Phase I clinical trial for spinal cord injury.